直接检测法 —— 荧光标记蛋白
产品特点
- 靶抗原预先标记了荧光素基团
- 可简化检测流程,节省检测时间
- 可避免因二抗交叉反应而引起的非特异性背景
> FITC-labeled (点击分子即可查看产品详情)-> 独有产品
BCMA | CD19 | CD22 | GPC3 | MSLN | Protein L |
> PE-labeled (点击分子即可查看产品详情)-> 独有产品
MSLN |
> 应用案例
293 cells were transfected with anti-CD19-scFv and RFP tag. 2e5 of the cells were stained with B. FITC-labeled Human CD19 (20-291) (Cat. No. CD9-HF2H2, 10 µg/ml) and C. FITC-labeled protein control. A. Non-transfected 293 cells and C. FITC-labeled protein control were used as negative control. RFP was used to evaluate CAR (anti-CD19-scFv) expression and FITC was used to evaluate the binding activity of FITC-labeled Human CD19 (20-291) (Cat. No. CD9-HF2H2). > 如需了解更多此产品信息,可点击:ACROBiosystems官网,输入货号,即可查看产品详情,也可直接拨打:400-682-2521进行咨询 ACROBiosystems作为专注于医药研发领域的蛋白供应商,利用专业的蛋白研发平台、蛋白标记平台、稳定株开发平台和流式细胞分析平台,开发了一系列包括非标记、生物素标记、荧光标记等多种形式的CAR-T靶点蛋白以及配套的流式细胞法检测CAR阳性率的protocol,以助力CAR-T的研发,加速CAR-T研发的进程。目前产品已覆盖BCMA,CD19,ROR1,EGFRVIII等20余个CAR-T热门靶点。 如需查看更多CAR-T产品信息,可点击:http://www.acrobiosystems.cn/L42-Car-T-Target.html 进行查看